Compare TCBK & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCBK | MLYS |
|---|---|---|
| Founded | 1975 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 1995 | 2023 |
| Metric | TCBK | MLYS |
|---|---|---|
| Price | $51.88 | $21.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $58.67 | $46.33 |
| AVG Volume (30 Days) | 247.1K | ★ 1.3M |
| Earning Date | 10-30-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.77% | N/A |
| EPS Growth | 6.94 | ★ 37.43 |
| EPS | ★ 2.10 | N/A |
| Revenue | ★ $53,445,000.00 | N/A |
| Revenue This Year | $7.44 | N/A |
| Revenue Next Year | $3.99 | N/A |
| P/E Ratio | $24.81 | ★ N/A |
| Revenue Growth | ★ 4.12 | N/A |
| 52 Week Low | $41.96 | $20.12 |
| 52 Week High | $61.71 | $47.65 |
| Indicator | TCBK | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 45.75 | 34.47 |
| Support Level | $50.39 | N/A |
| Resistance Level | $53.05 | $31.19 |
| Average True Range (ATR) | 0.90 | 1.23 |
| MACD | 0.14 | -0.24 |
| Stochastic Oscillator | 55.49 | 10.29 |
TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income. Its banking and financial services are provided through full-service branches and commercial banking offices across California.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.